Who pays for the vaccine?
Although varicella zoster virus vaccine is recommended for all children, the federal government does not fund this vaccine.
Parents therefore have to pay amounts varying from less than $60 to almost $100 per dose. Potential vaccinees should be advised to shop around for the cheapest price. Many private health insurance 'extras' policies provide partial reimbursement.
How safe is the vaccine?
Since 1995 over 40 million doses have been distributed in the USA. 6 The vaccine has been shown to be safe in healthy children. 7 If reactions occur, they are usually limited to fever or local reactions at the injection site. Skin rash occurs in about 7% of healthy vaccinees, either at the injection site or more generalised, and may be vesicular. Varicella zoster virus vaccine can be safely administered at the same time as other vaccines, although, if it is not given simultaneously, it should be given at least four weeks before or after other live vaccines. 4 There have only been five reports of severe reactions in immunised children and they were later found to be immunocompromised. 6 No one is known to have died as a result of the vaccine virus.
How effective is the vaccine?
Varicella zoster virus vaccine is highly effective in children and adults. A single dose completely protects 85% of immunised children against developing clinical chickenpox. Immunised children who are not fully protected will almost always develop only mild disease if exposed to varicella zoster virus; vaccine effectiveness against moderate or severe disease is 97%. 9 Recently there have been some varicella outbreaks where the effectiveness of the vaccine was lower than expected. 10, 11, 12, 13 Children immunised more than four years previously appeared at increased risk of breakthrough disease in these outbreaks, although almost all cases had mild disease. Despite having mild disease, immunised children with breakthrough disease are contagious and should be subject to the same school exclusion criteria used for other cases of chickenpox.
Can the vaccine be used to prevent chickenpox after someone has been exposed?
The vaccine has been shown to be effective in preventing chickenpox if given within three days of exposure to varicella zoster virus 14 , although it may still have some benefit if given up to five days after exposure. Vaccination has also been effective in stopping varicella outbreaks, but in this situation it is recommended that the advice of public health personnel should be sought. 2, 15, 16 When not effective at preventing disease, post-exposure varicella vaccine may lead to milder disease in vaccinees.
How long does vaccine-induced protection last?
The evidence currently suggests that the vaccine usually remains protective for at least 10 years after immunisation, although the proportion of protected people may decline gradually after the first few years. Protective levels among many children vaccinated in Japan have persisted more than 20 years after vaccination. 9 However, studies into the duration of effectiveness have assessed the vaccine in an environment where wild varicella zoster virus infections and natural boosting of immunity are common. Significant boosting of the varicella immune response has been reported after second injections given 4-6 years after the initial immunisation. 17 However, booster doses are not currently recommended. As the use of varicella zoster virus vaccine increases and exposure to wild-type virus decreases in the community, it is possible that the duration of protection may decrease. Should this prove to be the case, a booster dose of vaccine may be warranted.
Will there be an increased risk of disease in older age groups?
There have been concerns that, by vaccinating children, the burden of disease will be shifted to an older age group who are at greater risk for more severe disease. It is clear that the proportion of cases in older age groups will increase as more A study in the USA five years after the introduction of the vaccine highlighted that cases of varicella declined in both children and susceptible adults, and hospitalisations for complicated varicella also substantially declined. 18 Although this observation is reassuring, the effect of immunisation on the epidemiology of varicella zoster virus infections in the community will require ongoing surveillance.
What effect will the vaccine have on the future risk of herpes zoster?
Immunological boosting from circulating varicella zoster virus may protect adults from developing shingles. There is concern that this boosting will not occur as the proportion of children being vaccinated increases resulting in a short-to medium-term increase in cases of herpes zoster in adults. This effect has not yet been seen in the USA, although further surveillance will be required. There appears to be a reduced incidence of herpes zoster among immunised people, although the long-term risk is not yet known.
How should the vaccine be stored?
There are two varicella zoster virus vaccines available in 
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